| http://www.w3.org/ns/prov#value | - FASN expression is upregulated in a number of cancers including ovarian, breast, and prostate [78???80] so the discovery that orlistat was a novel inhibitor of FASN [81] triggered numerous studies into the efficacy of orlistat as a therapeutic agent for cancer. orlistat has been shown to prevent in vitro and in vivo growth of the prostate cancer cell line PC3 and to induce apoptosis. [81].
|
